ClinicalTrials.gg
CompletedNCT00687440Updated Jul 3, 2018Results posted

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

A Phase 2 interventional study of Pegylated Liposomal Doxorubicin and Docetaxel in Breast Neoplasm, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-07-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Jul 2005, registered May 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
53rd of 66
27 · median 57
Started
2005
with 4 others
Phase 2
37 of 67
2 open now
Registered
29th of 67
by date
Lead sponsor
5 of 67
Merck Sharp & Dohme LLC

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 53rd largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2005, is one of 37 in phase 2, and was the 29th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate, in a first stage, the safety (incidence of cardiac toxicity) of Caelyx in combination with Trastuzumab and Docetaxel; and in a second stage, the tumor response rate of this regimen. This study will be conducted in approximately 30 centers. A total of approximately 70 to 95 subjects will be enrolled.

03

Conditions studied

  • Breast Neoplasm

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must fulfill all the following criteria:

  • Females aged 18 to 70 years-old.
  • Willingness to participate in the study and comply with its procedures.
  • Documented diagnosis of breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 () overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +).
  • No prior chemotherapy for metastatic breast cancer.
  • or neo-adjuvant chemotherapy is allowed according to the following rules:

    • patients treated with anthracyclines if all the following conditions are met:

      • Doxorubicin total dose \<= 300 mg/m\^2
      • Epirubicin total dose \<= 480 mg/m\^2
      • Chemotherapy-free interval of > 12 months
    • no taxane-based adjuvant or neo-adjuvant chemotherapy is allowed;
    • patients treated with non-anthracycline/taxane adjuvant or neo-adjuvant chemotherapy regimens are freely eligible (i.e. cyclophosphamide/methotrexate/fluorouracil (CMF) or similar regimens).
  • At least one according to criteria.
  • Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment.
  • Complete Tumor baseline evaluation including a total body computed tomography (CT) scan within 4 weeks prior to start of treatment.
  • (LVEF) >= 50% as determined by echocardiogram or Multi Gated Acquisition (MUGA) scan.
  • World Health Organization (WHO) performance status 0,1.
  • > 3 months.
  • Laboratory requirements :

    • Hematology :

      • Neutrophils > 1.5 x 10\^9/L
      • > 100 x 10\^9/L
      • > 10 g/dL
    • Hepatic function:

      • Total \<= 1.25 x the upper-normal limits (UNL);
      • ASAT ( or SGOT), ALAT (Alanine aminotransferase or SGPT) \<= 2.5 x the upper-normal limits;
    • For patients with liver metastases:

      • Total bilirubin \< 1.5 x the UNL () ;
      • ASAT and/or ALAT \< 3 x the UNL;
    • Renal function :

      • Serum Creatinine \< 1.5 x the UNL.
  • Women of child bearing potential must have a negative serum pregnancy test and be using adequate .
  • Patients must be accessible for treatment and follow-up.

Exclusion criteria

Exclusion Criteria:

Patients will not be enrolled if any of the following criteria apply:

  • Prior chemotherapy for disease.
  • History of prior in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ).
  • Radiation to disease areas within 3 weeks of study initiation.
  • Symptomatic peripheral neuropathy > grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria.
  • Other serious illness or medical condition.
  • \< 50% as determined by echocardiogram or MUGA scan.
  • Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia.
  • History of significant neurologic or psychiatric disorders including dementia or seizures.
  • Active infection.
  • Active peptic ulcer, unstable diabetes mellitus or other for the use of dexamethasone.
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any drug within 30 days prior to study screening.
  • Concurrent treatment with used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (> 6 months) at low dose (\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible.
  • Taxane-based or neo-adjuvant chemotherapy \< 12 months.
  • Other concurrent chemotherapy, immunotherapy, radiotherapy or any other investigational medication, for the treatment of the tumor.
  • Pregnant or breast-feeding women.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Caelyx, Docetaxel, Trastuzumab

    Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx. Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab.

    Drug: Pegylated Liposomal Doxorubicin · Drug: Docetaxel · Drug: Trastuzumab

Interventions

  • Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.

    Also known as: Caelyx

  • Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.

    Also known as: Taxotere

  • Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had a Tumor Response, According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria

    Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD) response.

    Time frame: Week 09, Week 18, at the end of each patient's treatment, and at 3, 6, 9, and 12 months after end of treatment.

07

Results

Posted Feb 15, 2010

Participant flow

Participant flow — Overall Study
MilestoneCaelyx, Docetaxel, Trastuzumab
Started27
Completed15
Not completed12
Withdrew: Adverse event3
Withdrew: Lost to follow-up3
Withdrew: Lack of efficacy2
Withdrew: Death2
Withdrew: Other1
Withdrew: Missing1

Outcome measures

PrimaryNumber of Participants Who Had a Tumor Response, According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria

Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD) response.

Time frame:
Week 09, Week 18, at the end of each patient's treatment, and at 3, 6, 9, and 12 months after end of treatment.
Reported as:
Number · Participants
Number of Participants Who Had a Tumor Response, According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria
ParticipantsCaelyx, Docetaxel, Trastuzumab
Participants who had a complete tumor response2
Participants who had a partial tumor response13
Participants who did not have a tumor response11

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Caelyx, Docetaxel, Trastuzumab—6/27 (22.2%)21/27 (77.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventCaelyx, Docetaxel, Trastuzumab
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders2/27
NEUTROPENIABlood and lymphatic system disorders1/27
STOMATITISGastrointestinal disorders1/27
VOMITINGGastrointestinal disorders1/27
MUCOSAL INFLAMMATIONGeneral disorders1/27
PYREXIAGeneral disorders1/27
SEPSISInfections and infestations1/27
EJECTION FRACTION DECREASEDInvestigations1/27
METASTASES TO MENINGESNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/27
COMANervous system disorders1/27
Most frequent other events
Showing 10 of 24
Most frequent other events
EventCaelyx, Docetaxel, Trastuzumab
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders16/27
NAUSEAGastrointestinal disorders8/27
ASTHENIAGeneral disorders8/27
DIARRHOEAGastrointestinal disorders7/27
STOMATITISGastrointestinal disorders7/27
MUCOSAL INFLAMMATIONGeneral disorders6/27
PYREXIAGeneral disorders6/27
LEUKOPENIABlood and lymphatic system disorders5/27
NEUTROPENIABlood and lymphatic system disorders5/27
ALOPECIASkin and subcutaneous tissue disorders4/27

Baseline characteristics

Age, Customized
Age, Customized(years)Caelyx, Docetaxel, Trastuzumab
Number27
Sex: Female, Male
Sex: Female, Male(Participants)Caelyx, Docetaxel, Trastuzumab
Female27
Male0
Region of Enrollment
Region of Enrollment(participants)Caelyx, Docetaxel, Trastuzumab
Italy27
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Oct 2008, 39 months.

Results were first posted in Feb 2010, 1 year 3 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 39 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
StartActual
Jul 15, 2005
Primary completionActual
Oct 24, 2008
CompletionActual
Oct 24, 2008
Results first posted
Feb 15, 2010
Last update
Jul 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00687440
Collaborators
MDS Pharma Services
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Jul 15, 2005
Primary completion
Oct 24, 2008
Completion
Oct 24, 2008
Results posted
Feb 15, 2010
Last update
Jul 3, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal doxorubicin · Docetaxel · Trastuzumab

Start the discussion